What's behind Ionis Pharmaceuticals's latest 3.5% stock pullback?
Ionis Pharmaceuticals, Inc. (IONS) fell 3.45% after reporting a second-quarter adjusted loss and disappointing clinical trial results for its lead pipeline candidate. The move is reinforced by broad technical weakness, with the stock lingering below all major moving averages and immediate support threatened.
Highlights
- Ionis Pharmaceuticals reported a Q2 2026 adjusted loss per share of $0.43, reversing from the prior year's $0.86 profit.
- FDA review for zilganersen in Alexander disease remains in progress with a decision anticipated by September, while the phase III Wainua trial failed its main efficacy goal.
- Shares are under strong bearish pressure and technical indicators signal a high probability of continued downside, with expected trading between $49.22 and $53.66 over the next week.
Earnings miss and trial failure sharpen investor uncertainty
Ionis Pharmaceuticals reported second-quarter 2026 adjusted losses per share of $0.43, compared to adjusted earnings of $0.86 in the prior year. The company recorded Q2 revenue of $268 million and maintained a cash balance of $2.1 billion to support its drug development pipeline. A regulatory filing for FDA approval of zilganersen in Alexander disease remains under review, with a decision expected by September. The phase III CARDIO-TTRansform trial for Wainua in hereditary TTR amyloidosis, conducted with AstraZeneca, did not meet its primary endpoint.
Persistent downtrend as major supports and indicators align bearish
IONS remains under all major moving averages, trading below the MA-20 at $61.25, MA-50 at $69.89, and MA-200 at $75.26, signaling persistent bearish pressure across all timeframes. Near-term levels are defined by a ceiling at $52.65 and a floor at $51.43. Technical indicators show a strong negative bias: MACD signals a strong sell, ADX confirms a pronounced downtrend, RSI is oversold at 28.24, and CCI stands at -57.23. Both Stochastic RSI and Bull/Bear Power indicate that sellers dominate, with BBP also in oversold territory. The stock closed near session lows, experiencing heightened intraday volatility following a downside gap at the open.
Previously it was reported that Ionis Pharmaceuticals faced a significant setback and sustained bearish momentum following disappointing late-stage clinical trial results for Wainua. The current technical setup reinforces this negative outlook, with persistent downside pressure suggesting traders should monitor for a potential break below $49.22 as the next material risk.